TickerTalks
Browse all tickers →
TickerTalks›$HCAT
HCHCAT

Health Catalyst, Inc.

$HCAT·$130M·Medical - Healthcare Information Services·Healthcare
$1.71-0.9%YTD-27.2%1Y-44.2%
Price updated 23m ago·X counts updated 8d ago
HCHCAT
$HCATHealth Catalyst, Inc.
$1.71-0.87%51 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $HCAT on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

51X posts · last 7 days
Oct 1Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $HCAT's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 74% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data7 posts analyzed · as of 2026-08-30

Chatter is exclusively about the Lo0p HyperEVM cat memecoin, not Health Catalyst. Boosters cheer $HCAT running from a $50K share to $100K market cap, $20M in supply already burned through fees, $250K of platform volume processed and a locked-forever HyperSwap pool against HYPE. Posters call it 'the only thing worth buying in the hype trenches' and frame it as the first-mover cat token on the launchpad. Uniformly promotional.

Read what X is saying about $HCAT

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $HCAT — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Comeback attemptWinding up for a moveAI verdict · as of 2026-10-02

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Health Catalyst at $1.70 — new CEO Simeon Kohl just bought $105K post-appointment, chart is a lottery ticket.

Health Catalyst provides healthcare data analytics and clinical improvement services to US hospital systems. The stock is at $1.70, down 29% YTD, with a specific new-CEO-plus-insider-buy setup after Simeon Kohl was named CEO and President.

  • The P&L is small and softening: revenue fell 10.9% YoY to $70.8M last quarter at a -19% operating margin and 46% gross margin — the business is in operational distress, with analyst estimates calling -$1.53 EPS trajectory.
  • The new CEO Simeon Kohl's open-market purchase of 59,000 shares at $1.79 ($105K) immediately after his appointment is the specific conviction signal — plus the 2.7M-share RSU grant aligns his upside with execution.
  • Tami Reller board appointment (ex-Microsoft CFO, Nike, Pandora) is a legitimate governance strengthening — pairs with the CEO change to suggest a serious operational reset is underway.

Coiling resolves higher if Nov 9 earnings confirm the Kohl-led operational reset with specific cost-reduction and revenue-stabilization numbers. It resolves lower if revenue decline widens or a dilutive raise is needed; this is a specific micro-cap turnaround with modest insider conviction, not a fundamental compounder.

Differs from X sentimentThe X $HCAT cashtag is entirely about the Lo0p HyperEVM cat memecoin — $100K market cap, $20M supply burned through fees, locked-forever HyperSwap pool against HYPE — not Health Catalyst the healthcare analytics company, whose actual tape is driven by the Kohl CEO transition.

What to watch: Nov 9 earnings — revenue trajectory, operating margin recovery, cost-reduction progress under Kohl, cash runway. A revenue decline below $65M or dilutive raise is what breaks the coil lower; a specific operational-turnaround-plan announcement is what breaks it higher.

On the calendar: 2026-11-09 — Q3 FY26 earnings

Read the AI verdict on $HCAT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Data and analytics platform for healthcare systems, integrating clinical and operational data for performance improvement.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Healthcare Information Services sits in its cycle right now — and what that implies for $HCAT.

Medical - Healthcare Information Services · Healthcare

No material change from last week — AI-driven clinical workflow digitization and prior-authorization automation are the structural demand drivers.

What this means for $HCAT

Partial — Data and analytics platform for healthcare systems, integrating clinical and operational data for performance improvement.

Industry benchmark

10-name peer basket
+27.4%YTD
+10.8%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-0.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-18.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-19.2%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
6.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-99.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
46.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$0.04$0.03+33.9%
Q1 2026May 11, 2026$0.02$0.01+100.0%
Q4 2025Mar 12, 2026$0.08$0.09-11.1%
Q3 2025Nov 10, 2025$0.06$0.05+20.0%
Next earningsMon, Nov 9·consensus EPS $-0.02

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$70.8M-10.9%33.4%-9.5%$-1.53$13.6M
Q4 FY25$74.7M-6.2%52.7%4.4%$-1.28$9.6M
Q3 FY25$76.3M-0.0%49.5%-22.9%$-0.32$-5.3M
Q2 FY25$80.7M+6.3%47.4%-46.0%$-0.59$-8.8M

Forward consensus

3-year forecast · up to 4 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$247.8M$247.8M – $247.8M-$0.04-$0.04 – -$0.044
FY27$205.5M$200.7M – $210.4M$0.01-$0.13 – $0.114
FY28$227.8M$222.9M – $233.7M$0.13$0.13 – $0.131

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.29%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+0.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-1.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 59.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.545-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuySep 14Simeon KohlCEO59.0K sh$105K
+ 20 other (10 awards · 10 inkinds) in window

See when $HCAT insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsOct 53
3New insider — initial holdingsSep 163
8-KOfficer or director changeSep 148-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

Health Catalyst (HCAT) appointed Tami Reller to its Board of Directors as a Class III director effective October 1, 2026, filling a newly created seat from board expansion from 6 to 7 members, per recommendation of the Nominating Committee. The filing also includes a Reg FD investor presentation (Item 7.01). Routine governance action — board expansion and director appointment with no financial impact.

SC 13D/AActivist amendmentSep 8SC 13D/A
AI summary

Palogic Value Fund, LP (Palogic Capital Management, an investment advisor) filed an amended Schedule 13D on Health Catalyst (HCAT) disclosing beneficial ownership of 5,374,949 shares (7.1% of outstanding), comprising 5,366,087 shares in the fund and 8,862 shares across separately managed accounts. This is a notable activist-adjacent filing that coincides with a CEO change at Health Catalyst (new CEO Simeon Kohl appointed). Palogic's growing position and 13D filing signal potential advocacy for strategic or operational changes at the healthcare data analytics company.

8-KOfficer or director changeSep 88-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

Health Catalyst appointed Simeon Kohl as CEO, President, and Director on September 4, 2026, succeeding Ben Albert. This represents a significant leadership change at the healthcare analytics company, occurring at the same time as a major activist investor (Palogic Value Fund, 7.1% holder) filed an updated Schedule 13D. The combination of a new CEO and active large-holder engagement signals a potential strategic inflection point for Health Catalyst. Kohl's compensation terms and background were not detailed in the available excerpt.

8-KAcquisition completedAug 68-K — Item 1.02: Agreement terminated · Item 2.01: Acquisition completed · Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

HEALTH CATALYST, INC. (HCAT) reported Q2 2026 financial results on 2026-08-06, reporting financial results details in attached press release. The press release notes: below) together with cash on hand, voluntarily repaid in ful. Additional items: Item 1.02, Item 2.01, Item 7.01. Quarterly earnings are a material disclosure; investors should review the full press release for segment details and management commentary.

8-KShareholder voteJul 208-K — Item 5.07: Shareholder vote
AI summary

Health Catalyst, Inc. (HCAT) held its 2026 Annual Meeting on July 16, 2026, with 54.4M of 73.9M eligible shares represented. Stockholders elected two Class I directors — Justin Spencer (41.2M for, 0.9M withheld) and Mathew Arens (40.6M for, 1.5M withheld) — each to three-year terms expiring in 2029, and ratified Ernst & Young LLP as independent auditor for FY2026. No contested votes or notable withhold campaigns. Standard annual meeting housekeeping with no material market impact.

SC 13DActivist position (5%+)Jun 22SC 13D
AI summary

Schedule 13D filed by Palogic Value Management, LP reporting beneficial ownership of SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Health Catalyst, Inc. representing a 7% stake (4 shares), with investment intent. This SC 13D filing dated 2026-06-22 updates the holder's position and disclosed intentions.

+ 17 other (4 13Gs · 3 8-Ks · 2 10-Qs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com·35d agoHealth Catalyst Strengthens Its Board with the Appointment of Tami Rellerprnewswire.com·35d agoHealth Catalyst Appoints Simeon Kohl as Chief Executive Officer and Presidentglobenewswire.com·42d agoHsbc Holdings PLC Invests $809,000 in Health Catalyst, Inc. $HCATdefenseworld.net·48d agoHealth Catalyst to Participate in Upcoming Investor Conferenceglobenewswire.com·49d ago

In themes

Explore the broader themes this ticker is being talked about under.

Trending on X

More in Medical - Healthcare Information Services

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TEM$HTFL$HNGE$TDOC$BTSG$DOCS$SOPH$OPRX
Voices on X · last 7 days

No standout posts about $HCAT on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport